NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 22 May 2025

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Paul Arundel (Chair) Present for all items
2. Professor Iolo Doull (Vice Chair) Present for all items
3. Emtiyaz Chowdhury Present for all items
4. Carrie Gardner Present for all items
5. Tina Garvey Items 1.1 to 5.1.3
6. Professor Jonathan Ives Present for all items
7. Professor Dusko Ilic Present for all items
8. Dr Natalia Kunst Present for all items
9. Stuart Mealing Present for all items
10. Sara Payne Present for all items
11. Angharad Shambler Items 1.1 to 4.3.2

NICE staff (key players) present

Lorna Dunning, Associate Director Items 1.1 to 4.3.2

Leena Issa, Project Manager Items 1.1 to 4.3.2

Victoria Kelly, Health Technology Assessment Adviser Items 1.1 to 4.3.2

Janet Boadu, Health Technology Assessment Analyst Items 1.1 to 4.3.2

Richard Diaz, Associate Director Items 5.1 to 5.2.2

Vonda Murray, Project Manager Items 5.1 to 5.2.2

Alan Moore, Health Technology Assessment Adviser Items 5.1 to 5.2.2

Lauren Elston, Health Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Dan Gallacher, Birmingham Centre for Evidence and Implementation Science (BCEIS) Items 1.1 to 4.1.3

Mehdi Yousefi, Birmingham Centre for Evidence and Implementation Science (BCEIS) Items 1.1 to 4.1.3

Matt Stevenson, ScHARR Items 1.1 to 4.1.3

Sunhong Kwon, ScHARR Items 1.1 to 4.1.3

Clinical, Patient & NHS England experts present

Michelle Lannon, Consultant Haematologist, Clinical expert nominated by Anthony Nolan Items 1.1 to 4.1.3

Claire Roddie, Associate Professor Haematology, Clinical expert nominated by Autolus (company) Items 1.1 to 4.1.3

Sheree Grindell, Patient expert, nominated by Anthony Nolan Items 1.1 to 4.1.3

Lizzie Spear, Patient expert, nominated by Leukaemia UK Items 1.1 to 4.1.3

Peter Clark, CDF Clinical Lead, NHS England Items 1.1 to 4.2.1

James Richardson, CDF Specialty Adviser, NHS England Items 1.1 to 4.2.1

Laura Smith van Carroll, Patient expert, Head of Insight & Advocacy nominated by Metabolic Support UK Items 5.1 to 5.1.3

Zafar Aslam, Patient expert, nominated by Metabolic Support UK Items 5.1 to 5.1.3

Arunabha Ghosh, Consultant in Paediatric Inherited Metabolic Disease, Clinical expert, nominated by Metabolic Support UK Items 5.1 to 5.1.3

Spyros Batzios, Consultant in Paediatric Metabolic Medicine, Clinical expert, nominated by Company Items 5.1 to 5.1.3

Reena Sharma, Consultant Adult Metabolic Medicine, Clinical expert, Nominated by Immedica Pharma UK, and Metabolic Support UK Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Paul Arundel, welcomed members of the committee and other attendees present to the meeting.
	2. The Chair noted apologies from Annett Blochberger, Angharad Shambler (topic 2), Professor Ed Wilson and Dr Shehla Mohammed.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 3 April 2025.

### Appraisal of Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Autolus.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11496/documents).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Sara Payne, Professor Iolo Doull and Emtiyaz Chowdhury.
	2. Part 2a – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee discussed confidential information submitted for this item.
	3. Part 2b – Closed session (NHSE experts were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta11496)

### Evaluation of Evaluation of Pegzilarginase for treating arginase-1 deficiency [ID4029]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Immedica Pharma UK.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-hst10054/documents).
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Dr Paul Arundel.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Pegzilarginase for treating arginase-1 deficiency [ID4029] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-hst10054)

### Date of the next meeting

The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Thursday 19 June 2025 and will start promptly at 9.15am.